AssuredPartners Investment Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN

Key Points

• Institutional ownership increased: AssuredPartners Investment Advisors raised its Amgen stake by 191.2% in the second quarter to 10,651 shares worth $3.86 million. Institutional investors collectively own 76.5% of the company.
• Amgen beat quarterly expectations: The company reported adjusted earnings of $6.29 per share and revenue of $10.05 billion, exceeding analyst estimates, while revenue rose 9.5% year over year.
• Analyst sentiment remains mixed but targets are rising: Several firms raised their price targets, including BMO and Scotiabank to $450, though the overall consensus rating remains “Hold” with a $380.43 target. Amgen also declared a quarterly dividend of $2.52 per share, implying a 2.3% yield.

AssuredPartners Investment Advisors LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 191.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,651 shares of the medical research company's stock after acquiring an additional 6,994 shares during the period. AssuredPartners Investment Advisors LLC's holdings in Amgen were worth $3,857,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of AMGN. Shepherd Financial Partners LLC grew its stake in Amgen by 3.8% in the second quarter. Shepherd Financial Partners LLC now owns 4,462 shares of the medical research company's stock worth $1,616,000 after purchasing an additional 162 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Amgen by 1.0% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 21,433 shares of the medical research company's stock valued at $7,761,000 after purchasing an additional 203 shares in the last quarter. West Family Investments Inc. raised its position in Amgen by 1.7% during the 2nd quarter. West Family Investments Inc. now owns 1,833 shares of the medical research company's stock valued at $664,000 after purchasing an additional 30 shares in the last quarter. Empirical Asset Management LLC lifted its holdings in shares of Amgen by 92.2% in the 2nd quarter. Empirical Asset Management LLC now owns 2,925 shares of the medical research company's stock worth $1,059,000 after buying an additional 1,403 shares during the period. Finally, Chancellor Financial Group WB LP lifted its holdings in shares of Amgen by 7.7% in the 2nd quarter. Chancellor Financial Group WB LP now owns 728 shares of the medical research company's stock worth $264,000 after buying an additional 52 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Barclays raised their price target on Amgen from $360.00 to $380.00 and gave the company an "equal weight" rating in a research note on Friday, August 14th. Wall Street Zen raised shares of Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Canaccord Genuity Group increased their target price on shares of Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. BMO Capital Markets raised their target price on shares of Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Finally, Scotiabank boosted their price target on shares of Amgen from $385.00 to $450.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Amgen presently has a consensus rating of "Hold" and a consensus target price of $380.43.

Amgen Stock Down 2.0%

Shares of Amgen stock opened at $433.73 on Friday. The firm's 50 day moving average price is $377.35 and its 200-day moving average price is $361.40. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $443.20. The company has a market cap of $234.49 billion, a P/E ratio of 26.96, a PEG ratio of 4.09 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts predict that Amgen Inc. will post 22.89 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio is currently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Unusually heavy call-option activity points to increased bullish positioning. Investors purchased 79,035 call options, roughly 931% above typical volume, although options activity is speculative and does not guarantee future gains.
• Positive Sentiment: Argus raised its price target from $375 to $460 and upgraded Amgen to “Buy,” adding to the series of favorable analyst views. Argus price target report
• Positive Sentiment: Mizuho and Cantor Fitzgerald analysts also projected further appreciation for Amgen, reinforcing the bullish sentiment around the company’s earnings performance and pipeline. Mizuho Amgen forecast Cantor Fitzgerald Amgen outlook
• Positive Sentiment: Amgen has outperformed several major drugmakers in 2026, attracting investor interest as markets favor profitable pharmaceutical companies even without an obesity-drug franchise. Drugmaker stock performance comparison
• Neutral Sentiment: Biotech ETFs are benefiting from innovation, obesity-drug demand and merger activity, creating a favorable sector backdrop, though the article does not identify a specific new catalyst for Amgen. Biotech ETF growth article
• Negative Sentiment: Industry caution around obesity-drug development is a risk: investors are penalizing undifferentiated programs, and Amgen has reportedly trimmed some early-stage efforts. Obesity drug investment outlook

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company's stock.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source